Peter Dritschilo
President bij SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Vermogen: 3 483 $ op 31-05-2024
Profiel
Peter Dritschilo currently works at Shuttle Pharmaceuticals, Inc., as President & Chief Operating Officer from 2012 and Shuttle Pharmaceuticals Holdings, Inc., as President & Chief Operating Officer.
Mr. Dritschilo received his undergraduate degree from Georgetown University and Masters Business Admin degree from The GW School of Business.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 21-03-2024 | 6 560 ( 0.04% ) | 3 483 $ | 31-05-2024 |
Actieve functies van Peter Dritschilo
| Bedrijven | Functie | Begin |
|---|---|---|
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | President | 18-12-2012 |
Shuttle Pharmaceuticals, Inc.
 Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | President | 01-12-2012 |
Opleiding van Peter Dritschilo
| Georgetown University | Undergraduate Degree |
| The GW School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Shuttle Pharmaceuticals, Inc.
Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Health Technology |
